Background and importance Health systems have limited resources, and these should be used responsibly to optimise outcomes for patients. The ABC (pareto analysis for expenditure) and VEN (health impact) methodology was developed by the WHO to help hospitals evaluate current spending.
Aim and objectives A decision making system was developed for inventory management of chemotherapy agents and medicines to treat their adverse reactions (CA-MtADR). As these medicines are expensive, we formulated an ABC-VEN matrix as a combination of two analytical tools, to produce a budget optimising management system.
Material and methods Dispensing data for the first 6 months of 2019 from the haematology, oncology and chemotherapy departments were collected. ABC analysis was performed: class A accounted for 72% of total expenditure, class B for 23% and class C for 5%. The VEN tool was further extended to a score index (summarising the characteristics of the health impact of the medicines) grouped into three classes: class V for vital, class E for essential and class N for non-essential medicines. Crosstab ABC-VEN analysis resulted in three major categories: I (AV, BV, CV, AE), II (BE, CE) and III (AN, BN, CN).
Result Fifty-seven CA-MtADR were analysed. Expenditure for CA-MtADR was 40% of the total expenditure for medicines in the hospital. According to the ABC analysis, 7 medicines (12%) were class A, 12 medicines (21%) class B, and 38 (67%) class C. According to the VEN analysis, 9 medicines (16%) were characterised as V, 43 (75%) as E and 5 (9%) as N. According to the ABC-VEN crosstab analysis, category I (eg, daratumumab (ATC L01XC24)) included 16 medicines (28%), category II (eg, trastuzumab emtansine (ATC L01XC14)) 36 medicines (63%) and category III (eg, pantoprazole (ATC A02BC02)) 5 medicines (9%).
Conclusion and relevance ABC-VEN crosstab analysis revealed three categories of corresponding priority: CA-MtADR category I, including expensive and/or vital medicines which need patient oriented personalised stock management; CA-MtADR category II, medicines which should be monitored with special consideration to ensure availability (because they are essential); and CA-MtADR category III, medicines where stock is according to demand (due to low price). ABC, VEN and ABC-VEN analysis can assist in developing a robust approach to improve budgetary planning in hospitals.
References and/or acknowledgements No conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.